Alkion BioInnovations Secures €4.4 Million to Scale Sustainable Bioproduction of Vaccine Adjuvants
French biotech Alkion BioInnovations has announced a €4.4 million funding round to propel its sustainable bioproduction platform into industrial scale and strengthen its role in supplying critical vaccine ingredients and adjuvants. The financing marks a strategic step forward for the Versailles‑based company as it transitions its proprietary plant‑based production technologies from pilot phases toward GMP‑grade commercial readiness.
Alkion’s platform is built around innovative plant tissue technologies that use temporary immersion bioreactors and automated systems to cultivate plant biomass capable of yielding high‑value active compounds — including natural vaccine adjuvants such as QS‑21 and related saponins — with a sustainable, low‑resource footprint. The company positions its technology as a scalable and ecologically responsible alternative to traditional extraction methods that depend on wild harvesting or high‑intensity agriculture.
The €4.4 million financing round was led by GO Capital, a French impact investment firm that backs technology leaders in health, digital and environmental transition sectors. Joining GO Capital was Critical Path Ventures, a venture firm focused on early‑stage healthcare and medtech innovations. Their combined backing provides Alkion with the capital needed to scale its bioreactor systems, optimise extraction and purification processes for key adjuvants, and support collaborations aimed at improved vaccine formulations.
Alkion CEO Sarah‑Meryll Buet said the investment will help establish a competitive European source of QS‑21 and related adjuvants — components critical to enhancing the immune response in both prophylactic and therapeutic vaccines, including mRNA‑based approaches. Traditionally, QS‑21 has been sourced through unsustainable extraction from the bark of Quillaja saponaria, a tree native to Chile, creating supply constraints and environmental concerns. Alkion’s approach, by contrast, uses controlled plant biomass cultivation without harvesting natural forests, offering a path to both sustainability and industrial sovereignty.
The financing will support Alkion’s efforts to industrialise its proprietary bioproduction platform to GMP standards, enabling the production of pharmaceutical‑grade compounds that can be integrated into global vaccine supply chains. Scaling up from lab and pilot installations to full industrial bioreactors is a key strategic objective for the company as it prepares to meet regulatory requirements and address global demand.
In addition to GO Capital and Critical Path Ventures, Alkion has capitalised on significant European innovation support programmes in earlier stages of development. The company was a winner of the EIC Accelerator award, securing substantial backing to develop its pilot biorefinery infrastructure, and has participated in public‑private research initiatives that validate and extend its technological platform.
Investors see Alkion’s technology as relevant to multiple facets of both global health and sustainable biomanufacturing. GO Capital’s investment thesis emphasises impact technologies that can strengthen sovereignty in strategic sectors such as health and environmental transition, while Critical Path Ventures highlights the importance of enabling novel production routes for key pharmaceutical compounds. Together, their participation underscores confidence in Alkion’s vision of a scalable, circular bioproduction model.
Alkion’s wider mission extends beyond vaccine adjuvants to encompass a broader suite of high‑value active compounds derived from proprietary plant tissue culture techniques. The company has developed capabilities in areas such as recombinant proteins and other bioactives, with its research and development activities focusing on expanding applications across pharmaceutical and nutraceutical markets.
By leveraging patented cultivation and extraction technologies, Alkion aims to meet growing global demand for sustainably produced pharmaceutical ingredients while addressing supply‑chain vulnerabilities exposed by recent public health challenges. Its plant‑based platform targets scalability and consistency, with a potential impact on vaccine equity and global health preparedness.
With its recent funding secured and strategic partners onboard, Alkion BioInnovations is now positioned to advance its proprietary technology through industrialisation, regulatory readiness and broader market adoption. The €4.4 million round represents not just a financing milestone but a validation of the company’s potential to drive a sustainable, locally sourced production ecosystem for critical biopharmaceutical inputs in Europe and beyond.
